Latest Nitazoxanide Stories
-NIH Principal Investigator to Present Abstract and Poster at Conference on Retroviruses and Opportunistic Infections (CROI) PALO ALTO, Calif., Feb.
- In Phase 3 clinical trials, VIEKIRAX + EXVIERA cured 95-100 percent of genotype 1 chronic hepatitis C patients, with less than 2 percent of patients experiencing virologic failure,
MOSCOW, October 21, 2014 /PRNewswire/ -- Hepatera Ltd and its development partner MYR GmbH announced today the results of clinical trials investigating Myrcludex B in patients
Pharmacokinetics, Safety and Tolerability of NVR-1221 Support Advancement to Phase 1b Clinical Studies in Patients with Chronic HBV Infection DOYLESTOWN, Pa., Sept.
MILFORD, Mass., May 12, 2014 /PRNewswire/ -- Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel drugs to treat a number of medical
MOSCOW, March 6, 2014 /PRNewswire/ -- A group of 48 patients infected with the hepatitis B virus (HBV) have been enrolled in the phase IIa clinical trial
- Large; stout; burly.